Celcuity (Nasdaq: CELC) invites you to their Virtual Science Day for Investors.

During this informative event, Celcuity will provide an in-depth overview of its lead compound, the equipotent pan-PI3K/mTOR inhibitor gedatolisib, the importance of comprehensive, rather than selective, inhibition of the PI3K/mTOR pathway, and review its clinical development strategy.

In both the first and second-line setting in HR+/HER2- advanced breast cancer (ABC), gedatolisib has reported encouraging efficacy data that compared favorably to current SOC treatment options when it was combined with a CDK4/6 inhibitor and endocrine therapy. The results reported were comparable independent of the PIK3CA status of a patient’s tumor.

Gedatolisib is currently enrolling patients with HR+/HER2- ABC whose disease progressed while receiving a CDK4/6 inhibitor in a global registrational Phase 3 study. In early 2024, Celcuity expects to initiate a Phase 1b/2 study evaluating patients with metastatic castration resistant prostate cancer whose disease progressed while receiving an androgen receptor inhibitor.

Leading KOL’s will review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor types.

Participants will also have the opportunity to participate in a chat-based Q&A.

Celcuity | Investor Relations